107. Impact of Switching to an Antiretroviral Regimen Containing Tenofovir Alafenamide on Weight Gain and Development of Metabolic Side Effects

BACKGROUND: Tenofovir is a common backbone of many antiretroviral (ARV) regimens for the treatment of HIV. Although limited, data has shown that tenofovir alafenamide (TAF) may contribute to weight gain. Our study evaluated the impact on weight gain and metabolic effects of people living with HIV (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Darnell, Julia, Karris, Maile, Qin, Huifang, Hill, Lucas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778229/
http://dx.doi.org/10.1093/ofid/ofaa439.417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778229/
http://dx.doi.org/10.1093/ofid/ofaa439.417

Ejemplares similares